Table 1 Comparison of clinical traits of α-fetoprotein-producing gastric cancer and non-α-fetoprotein-producing gastric cancer patients a
From: Characteristic analysis of α-fetoprotein-producing gastric carcinoma in China
Characteristics | AFPGCs, n(%) | Non-AFPGCs, n(%) | Studies, n(study number) |
|---|---|---|---|
Gender, N | 74 | 808 | 3 (1, 2, 6) |
Male | 54 (73.0) | 579 (71.7) | |
Female | 20 (27.0) | 229 (28.3) | |
Tumor site | 54 | 483 | 3 (2, 5, 6) |
Antrum | 23 (42.5) | 144 (29.8) | |
Body of stomach | 15 (27.8) | 156 (32.3) | |
Cardia or bottom of stomach | 15 (27.8) | 177 (36.7) | |
Whole stomach | 1 (1.9) | 6 (1.2) | |
Diameter of tumor,bN | 83 | 989 | 5 (1 to 3, 5, 6) |
<3 cm | 19 (22.9) | 373 (37.7) | |
>3 cm | 64 (77.1) | 616 (62.3) | |
Diameter of tumor,bN | 53 | 567 | 2 (1, 6) |
<5 cm | 34 (64.2) | 487 (85.9) | |
>5 cm | 19 (35.8) | 80 (14.1) | |
Borrmann type, N | 39 | 442 | 2 (2, 3) |
I or II | 16 (41.0) | 197 (44.6) | |
III or IV | 23 (59.0) | 245 (55.4) | |
Histopathological type, N | 32 | 436 | 1 (1) |
Papillary cystadenocarcinoma | 3 (9.4) | 212 (48.6) | |
Tubular adenocarcinoma | 11 (34.3) | 45 (10.3) | |
Mucinous adenocarcinoma | 3 (9.4) | 94 (21.6) | |
Signet ring cell carcinoma | 6 (18.8) | 57 (13.1) | |
Undifferentiated | 9 (28.1) | 28 (6.4) | |
Differentiation degree, N | 86 | 919 | 4 (1, 2, 5, 6) |
Well or moderate | 12 (14.0) | 290 (31.6) | |
Poor or none | 74 (86.0) | 629 (68.4) | |
Serosal infiltration N | 67 | 614 | 4 (3 to 6) |
T1 or T2 | 26 (38.8) | 285 (46.4) | |
T3 or T4 | 41 (61.2) | 329 (53.6) | |
Lymph node metastasis,cN | 120 | 1291 | 6 (1 to 6) |
No | 18 (15.0) | 492 (38.1) | |
Yes | 102 (85.0) | 799 (61.9) | |
Lymph node metastasis,cN | 55 | 613 | 3 (2 to 4) |
0 | 6 (10.9) | 235 (38.3) | |
1 - 4 | 7 (12.7) | 212 (34.6) | |
> 4 | 42 (76.4) | 166 (27.1) | |
Liver metastasis, N | 120 | 1291 | 6 (1 to 6) |
Yes | 68 (56.7) | 255 (19.8) | |
No | 52 (43.3) | 1,036 (80.2) | |
Stage, N | 87 | 1049 | 4 (1 to 4) |
I | 4 (4.6) | 198 (18.9) | |
II | 14 (16.2) | 366 (34.9) | |
III | 23 (26.4) | 325 (31.0) | |
IV | 46 (52.8) | 160 (15.2) | |
VEGF expression, N | 21 | 241 | 1 (2) |
Positive | 19 (90.5) | 162 (67.2) |